SCHEMBL4673902

SCHEMBL4673902

O=C(C=C(O)c1nn[nH]n1)c1[nH]ncc1S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.33
AKR1B1 P15121 1/20 0.33
HTR2A P28223 4/20 0.32
IKBKB O14920 1/20 0.32
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
MMP9 P14780 1/20 0.32
MMP12 P39900 1/20 0.32
MMP13 P45452 1/20 0.32
MMP14 P50281 1/20 0.32
KCNH2 Q12809 2/20 0.32
MAPT P10636 1/20 0.31
CCNA2 P20248 1/20 0.30
CYP2D6 P10635 1/20 0.30
CXCR3 P49682 1/20 0.30
AKR1C3 P42330 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674683 0.89 AKR1B1 (0.33) AKR1B1MAPTCXCR3
SCHEMBL4675183 0.84 HTR2A (0.35) CDK2AKR1B1HTR2AIKBKBMMP1
SCHEMBL4673518 0.80 IKBKB (0.32) AKR1B1IKBKBMMP1MMP2MMP3
SCHEMBL4671614 0.80 MAPT (0.32) AKR1B1MMP1MMP2MMP3MMP9
SCHEMBL4672382 0.80 NPSR1 (0.41) AKR1B1IKBKBMMP1MMP2MMP3
SCHEMBL4673134 0.80 MAPT (0.32) AKR1B1MMP1MMP2MMP3MMP9
SCHEMBL4670604 0.79 CDK2 (0.39) CDK2AKR1B1HTR2AIKBKBMMP1
SCHEMBL4679011 0.79 AKR1B1 (0.41) AKR1B1HTR2AKCNH2CXCR3
SCHEMBL4678094 0.77 MAPT (0.34) CDK2MAPTCCNA2
SCHEMBL4672908 0.77 AKR1B1 (0.31) AKR1B1CXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CDK2 363/4885AKR1B1 17/4885HTR2A 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.